T1	intervention 12 22	gabapentin
T2	condition 45 85	paclitaxel induced peripheral neuropathy
T3	eligibility 414 438	Women with breast cancer
T4	control 549 556	placebo
T5	duration 561 568	2Â weeks
T6	outcome-Measure 650 682	relative frequency of neuropathy
T7	outcome-Measure 687 728	change in nerve conducting velocity (NCV)
T8	intervention-participants 730 736	Twenty
T9	control-participants 730 736	Twenty
T10	outcome 796 806	neuropathy
T11	outcome 946 982	rate of 2nd and 3rd grade neuropathy
T12	outcome 1048 1061	change in NCV
T13	intervention-value 1173 1178	17.7%
T14	control-value 1182 1187	61.0%
T15	outcome 1188 1212	decline in NCV for sural
T16	intervention-value 1217 1222	21.9%
T17	control-value 1226 1231	62.5%
T18	outcome 1232 1266	declines in NCV for peroneal nerve
